Following a financial assessment of the plant as part of the annual impairment testing in accordance with International Financial Reporting Standards, Clariant is to take an impairment of about CHF 225 million to the current asset value of its recently opened Sunliquid plant in Podari, Romania.

In a Q2 trading update, Solvay revealed that an impairment review is under way and likely to lead to a non-cash impairment of about €1.5 billion. This is the result of “the deterioration in short and mid term economic performance due to Covid-19,” the company said.